Biogen expects ~$2M pre-tax IPR&D charge for Q3, impact of ($0.01)/share

BIOGEN INC.

Preliminary estimate: acquired IPR&D, upfront & milestone expense of ~$2M pre-tax.
Estimated impact of ($0.01) per diluted share on both GAAP and non-GAAP EPS.
Q3 2025 results not yet finalized; subject to closing procedures and could differ.

item 2.02 item 9.01

BIOGEN INC. filing history →

Source: SEC EDGAR

accession 0000875045-25-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.